🌍·Jun 2, 2025Industry
ASCO 2025 Oral Presentation: Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial
Publisher
B
Bicara Therapeutics
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Bicara Therapeutics
- Region
- 最新
- Scope
- Industry
- Published
- June 2, 2025
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on bicara.com
Leave the platform to read the original full article on the publisher site.
Source: Bicara Therapeutics
Scope: Industry
Related coverage
More related coverage
SELLAS Life Sciences·21h ago
Company - Sellas Life Sciences
Hyman, Phelps & McNamara (FDA Law)·22h ago
WuXi AppTec’s 1260H Listing Brings the BIOSECURE Act Back to Center Stage
Sumitomo Pharma·1d ago
Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia
Menicon·1d ago